PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 103 filers reported holding PUMA BIOTECHNOLOGY INC in Q4 2021. The put-call ratio across all filers is 0.85 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $395 | -99.2% | 150 | -99.1% | 0.00% | – |
| Q2 2023 | $51,935 | +4.6% | 16,214 | -4.3% | 0.00% | – |
| Q1 2023 | $49,666 | -32.9% | 16,941 | -2.8% | 0.00% | – |
| Q4 2022 | $74,000 | +76.2% | 17,430 | -0.3% | 0.00% | – |
| Q3 2022 | $42,000 | 0.0% | 17,482 | +16.7% | 0.00% | – |
| Q2 2022 | $42,000 | +27.3% | 14,980 | -1.8% | 0.00% | – |
| Q1 2022 | $33,000 | -32.7% | 15,260 | -2.0% | 0.00% | – |
| Q4 2021 | $49,000 | -75.0% | 15,571 | -46.7% | 0.00% | – |
| Q3 2021 | $196,000 | +46.3% | 29,219 | +100.4% | 0.00% | – |
| Q2 2021 | $134,000 | +5.5% | 14,577 | +11.6% | 0.00% | – |
| Q1 2021 | $127,000 | +2.4% | 13,060 | +7.6% | 0.00% | – |
| Q4 2020 | $124,000 | -15.6% | 12,140 | -16.3% | 0.00% | – |
| Q3 2020 | $147,000 | +36.1% | 14,510 | +40.1% | 0.00% | – |
| Q2 2020 | $108,000 | +35.0% | 10,355 | +8.5% | 0.00% | – |
| Q1 2020 | $80,000 | – | 9,540 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HARVARD MANAGEMENT CO INC | 600,000 | $45,216,000 | 3.56% |
| Avalon Global Asset Management LLC | 32,900 | $2,479,000 | 1.79% |
| CORNERSTONE CAPITAL MANAGEMENT LLC | 495,145 | $37,314,000 | 1.58% |
| BB BIOTECH AG | 521,991 | $39,337,000 | 1.25% |
| WEATHERBIE CAPITAL, LLC | 137,041 | $10,327,000 | 1.20% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,686,668 | $428,527,000 | 1.19% |
| TOBAM | 318,384 | $23,994,000 | 0.94% |
| Orbimed Advisors | 1,195,500 | $90,093,000 | 0.91% |
| Capital International Sarl | 109,405 | $8,245,000 | 0.74% |
| CAPITAL INTERNATIONAL LTD /CA/ | 145,697 | $10,980,000 | 0.73% |